Advancements in Mpox Vaccine Development:A Comprehensive Review of Global Progress and Recent Data  

作　　者：Yuqian Zhai Yize Han Wenling Wang Wenjie Tan 

机构地区：[1]NHC Key Laboratory of Biosafety,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,China

出　　处：《Biomedical and Environmental Sciences》2025年第2期248-254,共7页生物医学与环境科学(英文版)

摘　　要：Since May 2022,a severe global Mpox epidemic has underscored the urgent need for a preventative vaccine.On September 16,2022,the mainland of China reported its first case of imported Mpox,which was subsequently followed by a significant rise in domestic infections commencing from June 2023.This alarming trend has escalated the likelihood of localized outbreaks and covert transmission,posing a heightened risk to public health.Notably,the United States,many European countries,and Japan have approved the use of smallpox vaccines for Mpox prevention and emergency vaccination post-exposure,based on their cross-protection efficacy.In recent years,virology research has broadened its scope to include investigations into various novel vaccine approaches,such as nucleic acid-based vaccines,protein subunit vaccines,and epitope peptide vaccines,and other related methodologies.This review offers a thorough examination of the current global landscape of Mpox prevalence,delves into the advancements in Mpox vaccine development,and highlights the progress achieved in Mpox vaccine research,serving as a valuable resource and providing technical insights essential for the effective prevention and control of Mpox.

关 键 词：Mpox vaccine Vaccinia virus Mpox virus Smallpox vaccine 

分 类 号：R392-33[医药卫生—免疫学]